Cogent Biosciences Inc. (NASDAQ: COGT) announced results from its PEAK Phase 3 trial showing bezuclastinib combined with sunitinib demonstrated superior ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE